scholarly journals Bifidobacterium-mediated high-intensity focused ultrasound for solid tumor therapy: comparison of two nanoparticle delivery methods

2020 ◽  
Vol 37 (1) ◽  
pp. 870-878 ◽  
Author(s):  
Chun Chen ◽  
Yaotai Wang ◽  
Yu Tang ◽  
Lu Wang ◽  
Fujie Jiang ◽  
...  
Keyword(s):  
Solid Tumor ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Tumor Therapy ◽  
High Intensity Focused Ultrasound ◽  
Delivery Methods ◽  
Nanoparticle Delivery ◽  
Solid Tumor Therapy

High intensity focused ultrasound in the treatment of small kidney tumours— The Oxford experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14645-14645
Author(s):  
T. A. Leslie ◽  
R. O. Illing ◽  
J. E. Kennedy ◽  
M. F. Wu ◽  
G. R. Ter Haar ◽  
...  
Keyword(s):  
Mr Imaging ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Tumor Therapy ◽  
Prospective Trial ◽  
Tumour Response ◽  
Skin Toxicity ◽  
High Intensity Focused Ultrasound ◽  
Initial Assessment ◽  
Renal Tumours

14645 Background: High-intensity focused ultrasound (HIFU) provides a potential non-invasive alternative to conventional therapies. We have been using the extracorporeal ultrasound-guided Model-JC Tumor Therapy System (HAIFU Technology Company, China) in clinical trials to evaluate the safety and feasibility of treating small renal tumours. Methods: Patients with renal tumours less than 4cm diameter and unsuitable for surgery were treated with HIFU were enrolled into this phase II prospective trial. Treatment was delivered under general anaesthesia in a single session using the Model-JC Tumor Therapy System. Magnetic resonance imaging (MRI) 12 days after treatment provided an initial assessment of response (technical success). Patients are followed-up with further MR imaging at 6 months and one year to gauge technique effectiveness. A total of 14 patients will be included in the trial. Results: Eight patients with kidney tumours have been treated to date. All eight have had pre- and 12-day post-treatment MR imaging. One patient was not included in the analysis as treatment was suspended due bowel interposition in the treatment field during therapy. MRI changes suggestive of kidney tumour response have been seen in 4/7 (57%) cases. Complete ablation has been seen in two cases and partial ablation in two cases. One patient remains disease free 12 months after HIFU. Mild transient discomfort was reported by 4/8 patients (50%), and moderate discomfort in 3/8 (38%) but more severe pain needing opiate analgesia has not been encountered in this series. Minor skin toxicity (1mm blister at the treatment site) was seen in two patients. All patients were discharged the day after the procedure. There have been no adverse effects on renal, haematological or hepatic function. Conclusions: Extracorporeal HIFU has the ability to completely ablate small renal tumours. Our early clinical experience suggests that HIFU treatment of kidney tumours is safe and extremely well tolerated. The reasons for the variability in observed response remain obscure, and reliability of tumour ablation will need to improve before extracorporeal HIFU can be proposed for wider clinical use. [Table: see text]

scholarly journals Pulsed High Intensity Focused Ultrasound Mediated Nanoparticle Delivery: Mechanisms and Efficacy in Murine Muscle

2009 ◽  
Vol 35 (3) ◽  
pp. 416-424 ◽  
Author(s):  
Brian E. O'Neill ◽  
Howard Vo ◽  
Mary Angstadt ◽  
King P.C. Li ◽  
Tim Quinn ◽  
...  
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Nanoparticle Delivery

DESIGN AND FABRICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND PHASED ARRAY FOR LIVER TUMOR THERAPY

2009 ◽  
Vol 21 (03) ◽  
pp. 187-192 ◽  
Author(s):  
Gin-Shin Chen ◽  
Jonathan Cannata ◽  
Ruibin Liu ◽  
Hsu Chang ◽  
K. Kirk Shung
Keyword(s):  
Liver Tumor ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Phased Array ◽  
Liver Tumors ◽  
Tumor Therapy ◽  
Electrical Power ◽  
Preliminary Test ◽  
Central Line ◽  
High Intensity Focused Ultrasound

Noninvasive surgery of the liver tumors has been carried out by using the high-intensity focused ultrasound (HIFU). However, the liver tumor can be moved by the human respirations and heartbeats, which may cause the ablation and damage of normal tissues during the sonications of HIFU. The purpose of this study was to design and fabricate a cylindrical HIFU phased array transducer for treating the moving liver tumor efficiently. The total number of the element was 512 but only 256 channels were required since the elements along the elevation direction were connected in pairs with respect to the central line of the array. Field II software was used to simulate the acoustic field, and a formula for predicting the spatial averaged intensity at focus was developed based on the practical factors. The results of the simulations showed that the cylindrical HIFU phased array in water had a dynamic focusing range from 145 to 175 mm in the depth direction and a steering range from -15 to 15 mm in azimuthal direction with respect to the center of the array. After the dissipation of cables and the attenuation of various media, the designed array could still generate the intensity at focus up to 1095 W/cm2 when the input electrical power was approximately 410 W. The prototype of the array was fabricated and the preliminary test was completed. The testing results showed that each element of the array prototype can work well.

scholarly journals Targeted Delivery of Controlled Release Nanoparticles to Brain Tumors Using Contrast Agent Microbubbles and High-Intensity Focused Ultrasound

2018 ◽  
Author(s):  
Richard J. Price
Keyword(s):  
Blood Flow ◽  
Controlled Release ◽  
Brain Tumors ◽  
Targeted Delivery ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Tumor Regression ◽  
High Intensity Focused Ultrasound ◽  
Nanoparticle Delivery ◽  
Flow Changes

High-Intensity Focused Ultrasound (HIFU) treatment of brain tumors is complicated by heating of the skull. Here, our goal is to overcome this limitation by developing an ultrasound-microbubble-based therapeutic approach that complements HIFU by mechanically-damaging tumor tissue, occluding blood flow, and depositing 5-FU bearing controlled-release nanoparticles into brain tumors at reduced power levels. Experiments for monitoring nanoparticle delivery, blood flow changes, and tumor regression will be performed using tumors implanted in mouse dorsal skinfold window chambers. We anticipate these that studies will result in the successful development of a delivery method and agent(s) suitable for preclinical testing with HIFU.

Sign in / Sign up

Export Citation Format

Share Document